Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults
- PMID: 15933223
- DOI: 10.1001/jama.293.24.3003
Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults
Erratum in
- JAMA. 2005 Dec 28;294(24):3092
Abstract
Context: Increasing reports of pertussis among US adolescents, adults, and their infant contacts have stimulated vaccine development for older age groups.
Objective: To assess the immunogenicity and reactogenicity of a tetanus-diphtheria 5-component (pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3) acellular pertussis vaccine (Tdap) in adolescents and adults.
Design, setting, and participants: A prospective, randomized, modified double-blind, comparative trial was conducted in healthy adolescents and adults aged 11 through 64 years from August 2001 to August 2002 at 39 US clinical centers.
Interventions: A single 0.5-mL intramuscular dose of either Tdap or tetanus-diphtheria vaccine (Td).
Main outcome measures: Antibody titers to diphtheria and tetanus toxoids for Tdap and Td were measured in sera collected from subsets of adolescents and adults, before and 28 days after vaccination. For pertussis antigens, titers in sera from Tdap vaccinees were assessed vs those from infants who received analogous pediatric diphtheria-tetanus-acellular pertussis vaccine (DTaP) in a previous efficacy trial. Safety was assessed via solicited local and systemic reactions for 14 days and adverse events for 6 months following vaccination.
Results: A total of 4480 participants were enrolled. For both Tdap and Td, more than 94% and nearly 100% of vaccinees had protective antibody concentrations of at least 0.1 IU/mL for diphtheria and tetanus, respectively. Geometric mean antibody titers to pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3 exceeded (by 2.1 to 5.4 times) levels in infants following immunization at 2, 4, and 6 months with DTaP. The incidence of solicited local and systemic reactions and adverse events was generally similar between the Tdap and Td groups.
Conclusions: This Tdap vaccine elicited robust immune responses in adolescents and adults to pertussis, tetanus, and diphtheria antigens, while exhibiting an overall safety profile similar to that of a licensed Td vaccine. These data support the potential routine use of this Tdap vaccine in adolescents and adults.
Comment in
-
The 5 component acellular pertussis vaccine combined with tetanus and diphtheria toxoids was efficacious in adolescents and adults.Evid Based Med. 2006 Apr;11(2):51. doi: 10.1136/ebm.11.2.51. Evid Based Med. 2006. PMID: 17213081 No abstract available.
Similar articles
-
Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.Pediatr Infect Dis J. 2000 Apr;19(4):276-83. doi: 10.1097/00006454-200004000-00003. Pediatr Infect Dis J. 2000. PMID: 10783014 Clinical Trial.
-
Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.Pediatrics. 2006 Apr;117(4):1084-93. doi: 10.1542/peds.2005-1759. Pediatrics. 2006. PMID: 16585302 Clinical Trial.
-
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.J Pediatric Infect Dis Soc. 2019 May 11;8(2):105-114. doi: 10.1093/jpids/pix113. J Pediatric Infect Dis Soc. 2019. PMID: 29438562 Free PMC article. Clinical Trial.
-
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000. Drugs. 2012. PMID: 22931522 Review.
-
Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.Paediatr Drugs. 2006;8(3):189-95; discussion 196. doi: 10.2165/00148581-200608030-00005. Paediatr Drugs. 2006. PMID: 16774298 Review.
Cited by
-
ERRATA CORRIGE.J Prev Med Hyg. 2021 Apr 29;62(1):E249-E260. doi: 10.15167/2421-4248/jpmh2021.62.1.1832. eCollection 2021 Mar. J Prev Med Hyg. 2021. PMID: 34322644 Free PMC article.
-
Cost-Effectiveness of Pertussis Vaccination Schedule in Israel.Vaccines (Basel). 2021 Jun 2;9(6):590. doi: 10.3390/vaccines9060590. Vaccines (Basel). 2021. PMID: 34199574 Free PMC article.
-
Immunogenicity and antibody persistence of diphteria-tetanus-acellular pertussis vaccination in adolescents and adults: a systematic review of the literature showed different responses to the available vaccines.J Prev Med Hyg. 2021 Jan 14;61(4):E530-E541. doi: 10.15167/2421-4248/jpmh2020.61.4.1832. eCollection 2020 Dec. J Prev Med Hyg. 2021. PMID: 33628957 Free PMC article. Review.
-
Defining Dysbiosis for a Cluster of Chronic Diseases.Sci Rep. 2019 Sep 9;9(1):12918. doi: 10.1038/s41598-019-49452-y. Sci Rep. 2019. PMID: 31501492 Free PMC article.
-
The effectiveness and safety of pertussis booster vaccination for adolescents and adults: A systematic review and meta-analysis.Medicine (Baltimore). 2019 Apr;98(16):e15281. doi: 10.1097/MD.0000000000015281. Medicine (Baltimore). 2019. PMID: 31008974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical